secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0000950170-22-007402
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q1 NUPLAZID sales $115.5M (+8% YoY); net loss widens to $113.1M on $60M Stoke payment
--------------------------------------------------------------------------------

- Q1 NUPLAZID net sales $115.5M (+8% vs $106.6M Q1 2021); net loss $113.1M ($0.70/sh) vs $66.4M loss in prior year.
- R&D expense surged to $128.9M from $57.0M, driven by $60M upfront payment to Stoke Therapeutics under license deal.
- Cash and investments $446.0M at March 31, 2022, down from $520.7M at Dec 31, 2021.
- FY2022 NUPLAZID net sales guidance reiterated at $510-$560M; FDA AdComm for pimavanserin in ADP set for June 17, 2022.
- Trofinetide NDA for Rett syndrome on track for mid-2022; Parag Meswani and Holly Valdiviez joined as senior commercial leads.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022007402/0000950170-22-007402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017022007402/acad-20220504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer